Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Hart

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
European Journal of Immunology|June 9, 2012
Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coliAndrew J Kassianos, Melinda Y Hardy, Xinsheng Ju, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 13, 2011
Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse modelLisa M Freeman, Alfred Lam, Eugene Petcu, et al.
The Journal of Experimental Medicine|May 19, 2010
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensSarah L Jongbloed, Andrew J Kassianos, Kylie J McDonald, et al.
Blood|October 31, 2002
Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expressionSlavica Vuckovic, Min Kim, Dailal Khalil, et al.
Molecular Oncology|July 25, 2019
CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiationEdward Abadir, Robin E Gasiorowski, Kaitao Lai, et al.
Journal of Immunological Methods|January 23, 2004
Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assayS Vuckovic, D Gardiner, K Field, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2015
A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancerRebecca L Prue, Frank Vari, Kristen J Radford, et al.
Haematologica|January 21, 2018
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphomaZiduo Li, Xinsheng Ju, Kenneth Lee, et al.
Journal of Leukocyte Biology|November 22, 2019
Distinguishing human peripheral blood CD16<sup>+</sup> myeloid cells based on phenotypic characteristicsPhillip D Fromm, Pablo A Silveira, Jennifer L Hsu, et al.
Leukemia|August 20, 2015
Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantationT A Seldon, R Pryor, A Palkova, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
European Journal of Immunology|June 9, 2012
Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coliAndrew J Kassianos, Melinda Y Hardy, Xinsheng Ju, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 13, 2011
Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse modelLisa M Freeman, Alfred Lam, Eugene Petcu, et al.
The Journal of Experimental Medicine|May 19, 2010
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensSarah L Jongbloed, Andrew J Kassianos, Kylie J McDonald, et al.
Blood|October 31, 2002
Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expressionSlavica Vuckovic, Min Kim, Dailal Khalil, et al.
Molecular Oncology|July 25, 2019
CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiationEdward Abadir, Robin E Gasiorowski, Kaitao Lai, et al.
Journal of Immunological Methods|January 23, 2004
Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assayS Vuckovic, D Gardiner, K Field, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2015
A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancerRebecca L Prue, Frank Vari, Kristen J Radford, et al.
Haematologica|January 21, 2018
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphomaZiduo Li, Xinsheng Ju, Kenneth Lee, et al.
Journal of Leukocyte Biology|November 22, 2019
Distinguishing human peripheral blood CD16<sup>+</sup> myeloid cells based on phenotypic characteristicsPhillip D Fromm, Pablo A Silveira, Jennifer L Hsu, et al.
Leukemia|August 20, 2015
Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantationT A Seldon, R Pryor, A Palkova, et al.
Pageof 9